Equities Analysts Issue Forecasts for OS Therapies Q1 Earnings

OS Therapies Inc (NYSE:OSTX) – Equities researchers at Brookline Capital Management issued their Q1 2025 earnings per share estimates for shares of OS Therapies in a research note issued to investors on Wednesday, April 2nd. Brookline Capital Management analyst K. Raja forecasts that the company will post earnings per share of ($0.11) for the quarter. The consensus estimate for OS Therapies’ current full-year earnings is ($0.64) per share. Brookline Capital Management also issued estimates for OS Therapies’ Q1 2025 earnings at ($0.11) EPS, Q2 2025 earnings at ($0.11) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.10) EPS and Q4 2025 earnings at ($0.10) EPS.

A number of other research analysts have also recently commented on OSTX. D. Boral Capital reiterated a “buy” rating and issued a $20.00 price target on shares of OS Therapies in a research note on Monday, March 31st. Lake Street Capital initiated coverage on OS Therapies in a research report on Wednesday. They issued a “buy” rating and a $19.00 target price for the company. Finally, Maxim Group boosted their price target on OS Therapies from $8.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, January 16th. Three research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $18.00.

OS Therapies Stock Performance

Shares of OS Therapies stock opened at $1.40 on Friday. The company’s 50 day moving average price is $1.77 and its two-hundred day moving average price is $2.68. OS Therapies has a fifty-two week low of $1.33 and a fifty-two week high of $7.00.

Insider Activity

In other news, major shareholder Shalom Auerbach sold 100,000 shares of the company’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $2.84, for a total value of $284,000.00. Following the sale, the insider now directly owns 2,431,211 shares of the company’s stock, valued at approximately $6,904,639.24. This represents a 3.95 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 13.80% of the company’s stock.

Hedge Funds Weigh In On OS Therapies

A hedge fund recently raised its stake in OS Therapies stock. CM Management LLC grew its holdings in OS Therapies Inc (NYSE:OSTX) by 120.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 110,044 shares of the company’s stock after purchasing an additional 60,044 shares during the quarter. CM Management LLC owned about 0.51% of OS Therapies worth $471,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.